Risk Minimisation Materials

Checklist For Prescribers - Ethinylestradiol 0.03mg/Drospirenone 3mg Tablets

Checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

For Healthcare Professionals

Important information for women - Ethinylestradiol 0.03mg/Drospirenone 3mg Tablets

Further information about the recommendations coming from a recent Europe-wide review of the safety of combined hormonal contraceptives, in particular the risk of blood clots.

For Healthcare Professionals

Patient Card - Ethinylestradiol 0.03mg/Drospirenone 3mg Tablets

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

For Healthcare Professionals

Yacella - Important Information for Women

The person who prescribes your contraception has given you this sheet to give you a bit more information about the recommendations coming from a recent Europe-wide review of the safety of combined hormonal contraceptives, in particular the risk of blood clots.

Yacella Checklist for Prescribers

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations

For Healthcare Professionals

Yacella HCP Letter

Recent changes made to Yacella.

For Healthcare Professionals

Yacella Patient Card

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Yervoy (ipilimumab) Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. This card was updated in October 2020. Changes to the card include: design/editorial updates and addition of visual elements such as anatomy icons. For the Healthcare Professional (HCP) section of the PAC, reference to Yervoy Specific management guidelines for immune-related adverse reactions (irARs) was removed and a statement instructing HCPs to complete the card with their contact information has been added.

Yervoy (ipilimumab) Patient Information Guide

The provision of this Patient Information Guide to patients is required by the terms of the Marketing Authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. This Patient Information Guide was updated in October 2020. Changes to the material include design/editorial updates and addition of visual elements such as anatomy icons. A statement instructing Healthcare Professionals (HCPs) to complete the Patient Alert Card with their contact info has been added and information on severe infusion reactions has been added under the “Other important side effects” section.

YESCARTA_Handling Guide

Guide to handling and method of administration: To minimize the potential risk of decrease in viability of the product loss of efficacy due to inappropriate preparation of the Yescarta infusion.

For Healthcare Professionals

YESCARTA_HCP educational guide

Healthcare provider (HCP) educational material - To inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions, and provide guidance on reporting these serious adverse reactions associated with Yescarta.

For Healthcare Professionals

YESCARTA_Patient Alert Card

Patient Alert Card - To inform patients of the risks of CRS and serious neurologic adverse reactions, associated with Yescarta.